The work we are reporting here shows that PTEN augmentation resulting from genetic or pharmacologic inhibition of PRL2 can be exploited therapeutically to prevent cancer development in cancers that develop independently from PTEN inactivation and PI3K/Akt signaling hyperactivation. Here, PTP4A2 is linked to cancer.